Outcomes of patients diagnosed with chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation: Results from a tertiary care center
| Autor: | Jeffrey H. Lipton, Fotios V. Michelis, Wilson Lam, Carol Chen, Auro Viswabandya, Zeyad Al-Shaibani, Arjun Datt Law, Rajat Kumar, Armin Gerbitz, Ivan Pasic, Swe Mar Linn, Dennis Dong Hwan Kim, Jonas Mattsson, Ram V Nampoothiri |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Performance status business.industry Chronic lymphocytic leukemia medicine.medical_treatment Hazard ratio Hematology General Medicine Disease Hematopoietic stem cell transplantation Total body irradiation medicine.disease Tertiary care hemic and lymphatic diseases Internal medicine medicine Overall survival business |
| Zdroj: | Hematology/Oncology and Stem Cell Therapy. |
| ISSN: | 1658-3876 |
| Popis: | BACKGROUND Allogeneic hematopoietic stem cell transplantation (allo-HCT) is currently the only curative treatment for patients with chronic lymphocytic leukemia (CLL). METHODS We analyzed the outcomes of 93 patients (median age: 52 years) who underwent allo-HCT at our center between 1989 and 2019. RESULTS After a median follow-up of 35 months, relapse was observed in 15.1% (n = 14) patients. The estimated 2-year non-relapse mortality, relapse-free survival, and overall survival (OS) were 38.1%, 54.2%, and 58.7%, respectively. The ECOG performance status ≥ 2 (hazard ratio [HR]: 4.1; p = .001) and use of total body irradiation (in a myeloablative conditioning regimen; HR: 2.64; p = .005) were predictive of poor OS after multivariable analysis. The occurrence of sinusoidal obstruction syndrome/veno-occlusive disease post-transplant was associated with poor survival (p = .001). CONCLUSION Although the use of kinase and bcl2 inhibitors may result in a decrease in the number and need of transplants, allo-HCT remains a viable option in selected patients with high-risk CLL and good performance status. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|